Lewis Acid-Promoted Three-Component Reactions of Propargylic Alcohols with 2-Butynedioates and Secondary Amines

Guangwei Yin, Yuanxun Zhu, Ping Lu,* and Yanguang Wang*

Department of Chemistry, Zhejiang University, Hangzhou 310027, P. R. China

Supporting Information

ABSTRACT: We report herein a three-component reaction of propargylic alcohols with 2-butynedioates and secondary amines, which furnished functionalized dihydroazepines. In the cases where benzylmethylamine and benzyl-*i*-propylamine were used as the secondary amine, the reaction afforded 2,5-dihydro-1*H*-pyrroles and 2,3-dihydro-1*H*-pyrroles, respec-



tively, as the major product along with the desired dihydroazepines. The reaction mode depends on the electronic and steric effect of the substitutents on the secondary amines used. A tentative mechanism for this cascade process is postulated. The key intermediate is ascribed to 1,3,4-pentatrien-1-amine, which is formed by trapping the in situ generating allenic carbocation with enamine. Because of the reactivity of 1,3,4-pentatrien-1-amine formed, different products were thus formed.

INTRODUCTION

Dihydroazepine and its analogues represent an important class of heterocyclic compounds because of their bioactivities and pharmaceutical applications.¹Three examples of the clinically used drugs containing the dihydroazepine ring are Imipramine, Carbamazepine, and Oxcarbazepine. In addition, a number of natural products contain this structural unit.² Therefore, a number of methodologies have been developed for the construction of these heterocyclic seven-membered rings.³ Classical approaches include the insertion of nitrenes, cyclization of diene-conjugated nitrile ylides,⁴ and intramolecular Heck reaction.⁵ Recently, transition metal-catalyzed cyclizations,⁶ [4+3] cycloadditions,⁷ [5+2] cycloadditions,⁸ and ring-closing methathesis9 have been reported. The known biological properties and the huge potential in drug discovery of these heterocyclic compounds still need the development of facile and efficient methodologies for their selective and diverse synthesis.

Because of the easy generation and the prosperous reactions, allenes have attracted much attention in organic synthesis, especially in the synthesis of heterocycles and carbocycles with high complexity.¹⁰ A practical way to form allenes is using suitable nucleophiles to trap the allenic carbocation intermediates, which could be generated in situ by the Meyer–Schuster rearrangement of propargylic alcohols.¹¹ Either Brønster acids or Lewis acids could efficiently catalyze this rearrangement. Using this strategy, a number of substituted allenes.¹² and allenamides.¹³ were synthesized. The substituted indenes,¹⁴ methylenecyclobutenes,¹⁵ and thiazoles were also constructed via a cascade process from propargylic alcohols.¹⁶

In our efforts to develop a cascade process, we wondered whether the allenic carbocation generated in situ from propargylic alcohols could be trapped by enamine to give a cascade reaction product. The enamine bearing two ester groups was derived from butynedioate and a secondary amine and is believed to be able to decrease its nucleophilicity.



Figure 1. Design blueprint for trapping the allenic carbocation.

A detailed description of the proposal is shown in Figure 1. Herein, we report the realization of this goal leading to a convenient method for the construction of dihydroazepines.

RESULTS AND DISCUSSION

To test this new process, we began by choosing 1,1,3triphenylprop-2-yn-1-ol (**3a**) and diethyl 2-(diethylamino)maleate¹⁷ as the coupling partners. The later was formed in situ in an exclusive *E*-configuration by the reaction between diethyl but-2-ynedioate (**1a**) and diethylamine (**2a**). To our delight, dihydroazepine **4a** was constructed in 73% yield when AlCl₃ was used as a catalyst (Table 1, entry 1). The structure of **4a** was determined by X-ray single-crystal analysis.¹⁸

Enlightened by this result, we optimized the reaction conditions for the formation of **4a**, and the results are summarized in Table 1. When the catalyst was changed to ZnCl_2 , FeCl₃, or I₂, **4a** was obtained in a yield of 41, 76, or 49%, respectively (Table 1, entries 2–4). Boron trifluoride etherate gave the best

```
Received: August 9, 2011
Published: September 23, 2011
```

Table 1. Screening for Reaction Conditions^a

COOEt COOEt 1a	NHEt ₂ 2a EtOOC H	Ph HO 3a catalyst solvent, T	≣—Ph •►	Ph Ph N 4a	1 -COOEt COOEt
entry	catalyst	solvent	temp	time (h)	yield $(\%)^b$
1	AlCl ₃	DCM	reflux	1	73
2	ZnCl ₂	DCM	reflux	1	41
3	FeCl ₃	DCM	reflux	1	76
4	I_2	DCM	reflux	2	49
5	$BF_3 \cdot Et_2O$	DCM	reflux	1	83
6	$\begin{array}{c} BF_3 \cdot Et_2O \ (10 \ mol \\ \%) \end{array}$	DCM	reflux	8	trace
7	FeCl ₃ (20 mol %)	DCM	reflux	12	40
8	$BF_3 \cdot Et_2O$	toluene	50 °C	1	72
9	$BF_3 \cdot Et_2O$	CH ₃ CN	50 °C	1	69
10	$BF_3 \cdot Et_2O$	THF	50 °C	1	12
11	$BF_3 \cdot Et_2O$	DMF	50 °C	1	trace
12	$BF_3 \cdot Et_2O$	DCE	80 °C	1	78
13	$BF_3 \cdot Et_2O$	DCM	rt	5	60
14 ^c	$BF_3 \cdot Et_2O$	DCM	reflux	1	65

^aReaction conditions: **1a** (1 mmol), **2a** (1 mmol), solvent (3 mL), rt, 10 min; **3a** (1 mmol), 4 Å molecular sieves (0.4 g), catalyst (1 mmol). ^bIsolated yield. ^cWithout 4 Å molecular sieves. yield among these catalysts (Table 1, entries 1-5). After the loading amount of boron trifluoride etherate had been decreased to 10 mol %, only a trace amount of 4a was detected by thin layer chromatography (Table 1, entry 6). Similarly, after the amount of FeCl₃ had been decreased to 20 mol %, 4a was isolated in a relatively lower yield in comparison with the use of an equivalent molar amount of FeCl₃ (Table 1, entries 3 and 7). Changing the solvent to toluene, acetonitrile (CH₃CN), or tetrahydrofuran (THF) also decreased the yield of 4a (Table 1, entries 8-10). N,N-Dimethylformamide (DMF) did not work for this transformation (Table 1, entry 11). Either increasing or decreasing the reaction temperature influenced the isolated yield (Table 1, entries 12 and 13). The presence of a 4 Å molecular sieve would be beneficial for the reaction (Table 1, entry 14). Thus, the optimized reaction condition was established (Table 1, entry 5).

As the next step, we tested the substrate scope. As shown in Figure 2, propargylic alcohols, synthesized from *para*-substituted phenylacetylenes and symmetrical benzophenones, afforded the corresponding dihydroazepine derivatives 4b-e in good yields (76–85%). The effect of the substituent on the *para* position of phenyl acetylene was not apparent no matter if it was electron-withdrawing (4d) or electron-donating (4e). A propargylic alcohol derived from aliphatic alkyne and benzophenone produced 4f in 55% yield, while 1,1-diphenylprop-2-yn-1-ol afforded 4g in 40% yield only.



Figure 2. Structures of dihydroazepines 4b-q and their yields.

A propargylic alcohol derived from 4,4'-dimethylbenzophenone or fluorenone reacted with enamine generated from dimethyl but-2-ynedioate (1b) and diethylamine (2a) furnished 4h and 4i in 71 and 53% yields, respectively. Propargylic alcohol derived from unsymmetrical ketone also worked for the reaction to give 4j in 60% yield. An acetophenone-derived alcohol gave 4k in a slightly lower yield. The enamine component was formed in situ for this cascade reaction. The formation of diethyl 2-(diethylamino)maleate was confirmed by characterizing the isolated enamine from the mixture of diethyl but-2-ynedioate (1a) and diethylamine.¹⁹ Dipropylamine (2b), dibutylamine (2c), dibenzylamine (2d), and cyclic secondary amines, such as pyrrolidine (2e) and piperidine (2f), also worked well for this reaction to afford the corresponding products 4l-q in yields between 64 and 81%.

When morpholine (2g) was used, a highly strained molecule 5 $(31\% \text{ yield})^{20}$ was isolated along with the desired product 4r (34% yield) (Scheme 1). When the reaction temperature was

Scheme 1. Formation of 4r and 5



increased to 80 °C, however, **4r** could be obtained as a major product. It was noticed by the varied-temperature NMR that the isolated **5** could be converted to **4r** at higher temperatures (see the Supporting Information).

We also examined the amines with two different alkyl groups, such as *N*-benzylethanamine (2h), and obtained the expected dihydroazepines 4s (59% yield) and 4t (52% yield) (Scheme 2).





However, benzylmethylamine (2i) afforded 5-methylene-2,5dihydro-1*H*-pyrroles **6a** (45% yield) and **6b** (56% yield) in majority except for the desired dihydroazepines **4u** (32% yield) and 4v (20% yield) (Scheme 3). Other unexpected products were also isolated when *N*-benzylpropan-2-amine (2j) was

Scheme 3. Formation of 4u-x, 6, and 7



tested. In this case, 2,3-dihydro-1*H*-pyrroles 7a (49% yield) and 7b (52% yield) were constructed besides the desired products 4w (23% yield) and 4x (16% yield). Structures of $6b^{21}$ and $7a^{22}$ were confirmed by X-ray single-crystal diffraction.

In the case where diisobutylamine (2k), a bulky secondary amine, was used (Scheme 4), we isolated dihydroazepine 4y

Scheme 4. Formation of 4y and 8



(17% yield) and a ring-opening dienamine 8 (58% yield).²³ We also observed that the resulting dihydroazepine 4y was unstable and easily underwent hydrolysis in the presence of a trace amount of water to yield dienamine 8 (see the Supporting Information).

Finally, we examined the enamine²⁴ derived from methyl propiolate (1c) (Scheme 5) and found that it reacted with 3a to afford 2,4-dienal 9 in 52% yield. Noteworthy is the fact that 2,4-dienals are useful conjugated carbonyl compounds in organic synthesis.²⁵

On the basis of these results, we postulated a possible mechanism for the formation of 4-8 (Scheme 6). Reaction of 1

The Journal of Organic Chemistry

and 2 results in the formation of enamine A, which is an electron-deficient enamine in comparison to an alkylated one because of the electron withdrawing nature of two ester groups. A suitably traps the allenic carbocation B that is formed in situ through the Meyer-Schuster rearrangement of 1,1,3-triphenylprop-2-yn-1-ol (3a) to generate iminium intermediate C with a β -hydrogen. Subsequent deprotonation of C forms a betterconjugated intermediate D, possessing a chain of 1,3,4pentatrien-1-amine. As electrons flow as indicated in the D structure, an azomethine ylide E^{26} is generated. Intramolecular 1,6-Michael addition of E^{27} gives dihydroazepine ring 4, while intramolecular 1,4-Michael addition of E forms 2,3-dihydro-1Hpyrrole ring 7 in the case of N-benzylpropan-2-amine (2e). When morpholine is used as a substrate, a four-membered ring 5 is obtained via intermediate F, which is the resonance structure of D. The reactivity of the iminium of F is obvious because of the inductive effect of the oxygen in the morpholine ring, 28 which results in the formation of 5. 5 is unstable because of the ring strain. It undergoes ring opening under heat and regenerates F, which produces the thermodynamically favored 4r. When benzylmethylamine (2d) is used as the substrate, the nitrogen atom of D nucleophilically attacks the central carbon of allene to form a zwitterion intermediate G. Intramolecular migration of the benzyl group of G results in the formation of 2,5-dihydro-1H-pyrrole ring 6. In the case where bulky





Scheme 6. Postulated Mechanism for the Formation of 4-8

diisobutylamine (2f) is used, E can undergo a protonation at its benzylic position to produce imminium H. Hydrolysis of H leads to the formation of 8 and isobutyl aldehyde.

Formation of 9 could be understood as shown in Scheme 7. 1,3,4-Trienamine K is formed from 1c, 2a, and 3a through a

Scheme 7. Postulated Mechanism for the Formation of 9



pathway similar to that of the formation of **D** in Scheme 6. Compared with enamine **D**, bearing two electron-withdrawing groups, **I** is more electron-rich. Therefore, the central carbon of allene in **K** prefers protonation, resulting in the formation of 2,4-dieniminium **L**, which finally undergoes hydrolysis to form 2,4-dienal **9**.

In conclusion, we developed a one-pot reaction of 2butynedioates with secondary amines and propargylic alcohols in the presence of a Lewis acid. Generally, the reaction furnished functionalized dihydroazepines with a heterocyclic



seven-membered ring. In some cases, 2,5-dihydro-1*H*-pyrrole, 2,3-dihydro-1*H*-pyrrole, and dienamine were also formed along with the desired dihydroazepines, depending on the electronic effect and the steric effect of the secondary amines. A tentative mechanism for the formation of dihydroazepines and by-products is discussed, and it involves enamine, allenic carbocation, 1,3,4-pentatrien-1-amine, and azomethine intermediates. The key intermediate is ascribed to 1,3,4-pentatrien-1-amine, which is formed by trapping the in situ generating allenic carbocation with enamine.

EXPERIMENTAL SECTION

General Methods. Infrared spectra were recorded with a FTIR spectrometer. ¹H NMR spectra were recorded at 400 or 500 MHz using TMS as an internal standard and ¹³C NMR spectra at 75, 100, or 125 MHz using CDCl₃ as an internal standard. The following abbreviations are used to describe peak patterns where appropriate: b, broad; s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Coupling constants are reported in hertz. HRMS data were obtained using EI ionization. Melting points were measured with a micro melting point apparatus.

The propargylic alcohols were prepared according to the published methods.²⁹ Dichloromethane (DCM) was distilled from CaH_2 under a N_2 atmosphere. Molecular sieves (4 Å) were activated by being baked in a muffle oven. Other materials were purchased from common commercial sources and used without additional purification.

General Procedure for the Preparation of Dihydroazepines 4–8. To a solution of secondary amine 2 (0.5 mmol) in dry dichloromethane (3 mL) was added 2-butynedioate 1 (0.5 mmol), and the solution was stirred for 10 min at room temperature. Then, propargylic alcohol 3 (0.5 mmol), 4 Å molecular sieves (200 mg), and BF₃·Et₂O (0.5 mmol) were added in sequence. After being stirred at reflux temperature for 1 h, the mixture was evaporated under vacuum. The product was isolated by silica gel column chromatography with a hexane/EtOAc/Et₃N mixture (10:1:0.1, v/v/v).

Diethyl 1-ethyl-7-methyl-4,6,6-triphenyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (**4a**): yellow solid; 83% yield; mp 158–159 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, *J* = 7.9 Hz, 2H), 7.36 (d, *J* = 8.2 Hz, 2H), 7.32–7.22 (m, 4H), 7.21–7.11 (m, 6H), 7.07 (t, *J* = 6.8 Hz, 1H), 6.06 (s, 1H), 4.64 (q, *J* = 6.2 Hz, 1H), 4.11 (q, *J* = 7.1 Hz, 2H), 3.82–3.54 (m, 2H), 2.96–2.53 (m, 2H), 1.29 (t, *J* = 6.9 Hz, 3H), 1.24–1.15 (m, 6H), 0.74–0.66 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.8, 166.2, 149.0, 147.4, 146.0, 142.2, 140.9, 132.1, 128.3, 127.93, 127.86, 127.8, 127.6, 126.5, 126.2, 125.93, 125.86, 102.9, 62.6, 61.7, 61.6, 60.1, 53.0, 19.2, 16.1, 13.6, 13.3; IR (KBr) ν 2980, 1733, 1691, 1597, 1546, 1444, 1371, 1256, 1089, 704 cm⁻¹; HRMS (EI) *m*/z calcd for C₃₃H₃₅NO₄ 509.2566, found 509.2567.

Diethyl 4-(4-bromophenyl)-1-ethyl-7-methyl-6,6-diphenyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (**4b**): white solid; 85% yield; mp 157–158 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.42–7.33 (m, 4H), 7.30 (t, *J* = 7.6 Hz, 4H), 7.21–7.14 (m, 3H), 7.13–7.04 (m, 3H), 6.03 (s, 1H), 4.65 (q, *J* = 6.2 Hz, 1H), 4.10 (q, *J* = 7.1 Hz, 2H), 3.91–3.55 (m, 2H), 3.02–2.55 (m, 2H), 1.29 (t, *J* = 7.0 Hz, 3H), 1.23–1.13 (m, 6H), 0.78 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.4, 166.0, 148.8, 147.8, 145.0, 142.0, 140.0, 132.4, 130.9, 128.4, 128.2, 127.8, 127.7, 126.03, 125.98, 119.9, 102.2, 62.7, 61.7, 61.6, 60.2, 53.1, 19.2, 16.1, 13.6, 13.5; IR (KBr) ν 1281, 1733, 1690, 1544, 1446, 1367, 1255, 1142, 1091, 701 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₃₃H₃₄BrNO₄ 587.1671, found 587.1678.

Diethyl 1-ethyl-7-methyl-6,6-diphenyl-4-(p-tolyl)-6,7-dihydro-1Hazepine-2,3-dicarboxylate (**4c**): yellow solid; 86% yield; mp 142– 143 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.36 (d, *J* = 8.1 Hz, 2H), 7.33–7.26 (t, *J* = 8.1 Hz, 4H), 7.21–4.11 (m, 5H), 7.11–7.03 (m, 3H), 6.04 (s, 1H), 4.63 (q, *J* = 6.1 Hz, 1H), 4.10 (q, *J* = 7.1 Hz, 2H), 3.87–3.55 (m, 2H), 3.03–2.50 (m, 2H), 2.31 (s, 3H), 1.29 (t, *J* = 6.9 Hz, 3H), 1.24–1.12 (m, 6H), 0.73 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.9, 166.3, 149.1, 147.2, 143.1, 142.3, 140.7, 135.7, 131.7, 128.5, 128.3, 128.0, 127.8, 127.6, 126.4, 125.9, 125.8, 103.1, 62.6, 61.7, 61.6, 60.1, 53.0, 21.0, 19.2, 16.1, 13.6, 13.4; IR (KBr) ν 2976, 1741, 1686, 1547, 1445, 1258, 1220, 1088, 1025, 707 cm $^{-1};$ HRMS (EI) m/z calcd for $\rm C_{34}H_{37}NO_4$ 523.2624, found 523.2631.

Diethyl 1-ethyl-4-(4-fluorophenyl)-7-methyl-6,6-diphenyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (**4d**): yellow solid; 81% yield; mp 164–165 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.42–7.33 (m, 4H), 7.30 (t, *J* = 7.7 Hz, 2H), 7.21–7.04 (m, 6H), 6.95 (t, *J* = 8.6 Hz, 2H), 6.02 (s, 1H), 4.65 (q, *J* = 6.1 Hz, 1H), 4.10 (q, *J* = 7.1 Hz, 2H), 3.88– 3.55 (m, 2H), 3.01–2.55 (m, 2H), 1.29 (t, *J* = 7.0 Hz, 3H), 1.23–1.12 (m, 6H), 0.78 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.6, 166.1,161.6 (d, *J* = 243 Hz), 148.9, 147.5, 142.1, 142.0 (d, *J* = 3.1 Hz), 139.9, 132.0, 128.4, 128.0, 127.9, 127.74, 127.66, 126.0 (d, *J* = 5.3 Hz), 114.6 (d, *J* = 21.2 Hz), 102.7, 62.7, 61.63, 61.59, 60.2, 53.1, 19.2, 16.1, 13.6, 13.5; IR (KBr) ν 2983, 1735, 1710, 1553, 1504, 1444, 1266, 1219, 1085, 755, 706 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₃₃H₄₄FNO₄ 527.2472, found 527.2464.

Diethyl 1-ethyl-4-(4-methoxyphenyl)-7-methyl-6,6-diphenyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (**4e**): white solid; 76% yield; mp 120–121 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.38–7.26 (m, 6H), 7.21–7.10 (m, 5H), 7.07 (t, *J* = 6.7 Hz, 1H), 6.80 (d, *J* = 8.6 Hz, 2H), 6.01 (s, 1H), 4.64 (q, *J* = 6.2 Hz, 1H), 4.10 (q, *J* = 7.1 Hz, 2H), 3.86–3.57 (m, 5H), 2.99–2.54 (m, 2H), 1.28 (t, *J* = 7.0 Hz, 3H), 1.23–1.08 (m, 6H), 0.78 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.9, 166.2, 158.3, 149.1, 147.0, 142.3, 140.3, 138.6, 131.2, 128.3, 128.0, 127.8, 127.6, 127.5, 125.9, 125.8, 113.2, 103.2, 62.7, 61.6, 60.1, 55.3, 53.0, 19.2, 16.1, 13.6; IR (KBr) ν 2978, 1735, 1690, 1610, 1547, 1510, 1255, 1219, 1089, 1035, 768 cm⁻¹; HRMS (EI) *m/z* calcd for C₃₄H₃₇NO₅ 539.2672, found 539.2681.

Diethyl 4-butyl-1-ethyl-7-methyl-6,6-diphenyl-6,7-dihydro-1Hazepine-2,3-dicarboxylate (4f): white oil; 55% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.35–7.28 (m, 4H), 7.22–7.15 (m, 1H), 7.13 (t, *J* = 7.5 Hz, 2H), 7.06–6.98 (m, 3H), 5.95 (s, 1H), 4.47 (q, *J* = 6.2 Hz, 1H), 4.30–4.20 (m, 1H), 4.16–4.00 (m, 3H), 2.83–2.78 (m, 1H), 2.73–2.61 (m, 1H), 2.48–2.34 (m, 1H), 2.29–2.16 (m, 1H), 1.52– 1.09 (m, 16H), 0.85 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 169.6, 166.6, 149.4, 145.2, 143.1, 138.3, 129.3, 128.2, 128.1, 128.0, 127.4, 125.75, 125.74, 104.8, 61.4, 61.3, 60.5, 52.3, 38.4, 33.2, 23.0, 18.7, 15.7, 14.1, 13.9, 13.6; IR (film) ν 2956, 1731, 1704, 1549, 1445, 1369, 1256, 1147, 1086, 749, 701 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₃₁H₃₉NO₄ 489.2879, found 489.2882.

Diethyl 1-ethyl-7-methyl-6,6-diphenyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (**4g**): white oil; 40% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.42–7.32 (m, 4H), 7.27–7.19 (m, 1H), 7.18–7.02 (m, 4H), 6.89 (d, J = 7.7 Hz, 2H), 6.03 (d, J = 12.2 Hz, 1H), 4.42 (q, J = 6.1 Hz, 1H), 4.29–7.16 (m, 4H), 2.82–2.67 (m, 1H), 2.10–1.89 (m, 1H), 1.36–1.26 (m, 6H), 1.22–1.13 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 168.1, 166.3, 150.6, 147.6, 145.2, 128.3, 128.1, 127.6, 126.5, 126.3, 126.1, 98.7, 62.0, 61.6, 61.4, 60.4, 51.2, 16.9, 15.1, 14.3, 13.7; IR (film) ν 2982, 1737, 1689, 1543, 1366, 1255, 1194, 1091, 729, 698 cm⁻¹; HRMS (EI) m/z calcd for C₂₇H₃₁NO₄ 433.2253, found 433.2250.

Dimethyl 1-ethyl-7-methyl-4-phenyl-6,6-di-p-tolyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (**4h**): white solid; 71% yield; mp 161–162 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.37 (d, *J* = 7.3 Hz, 2H), 7.25 (dd, *J*₁ = 12.6 Hz, *J*₂ = 7.6 Hz, 4H), 7.17 (t, *J* = 7.3 Hz, 1H), 7.09 (d, *J* = 8.0 Hz, 2H), 7.03–6.93 (m, 4H), 6.06 (s, 1H), 4.58 (q, *J* = 6.2 Hz, 1H), 3.69 (s, 3H), 3.17 (s, 3H), 2.92–2.53 (m, 2H), 2.28 (s, 3H), 2.23 (s, 3H), 1.27 (t, *J* = 7.0 Hz, 3H), 1.16 (d, *J* = 6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.4, 166.8, 147.0, 146.2, 146.0, 140.4, 139.7, 135.3, 132.7, 129.0, 128.4, 127.9, 127.7, 127.6, 126.3, 126.1, 103.1, 62.1, 61.1, 53.1, 52.5, 51.2, 20.9, 20.8, 19.0, 15.8; IR (KBr) ν 2947, 1738, 1699, 1557, 1431, 1262, 1223, 910, 734, 702 cm⁻¹; HRMS (EI) *m*/z calcd for C₃₃H₃₅NO₄ 509.2566, found 509.2564.

Dimethyl 1-ethyl-2-methyl-5-phenyl-1,2-dihydrospiro[azepine-3,9'-fluorene]-6,7-dicarboxylate (4i): white solid; 53% yield; mp 114–115 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.73 (dd, J_1 = 16.1 Hz, J_2 = 7.7 Hz, 2H), 7.43–7.31 (m, 4H), 7.31–7.12 (m, 7H), 5.89 (s, 1H), 3.86 (s, 3H), 3.18 (s, 3H), 3.10–2.99 (m, 2H), 2.37–2.20 (m, 1H), 1.35 (d, J = 6.7 Hz, 3H), 1.00 (t, J = 6.9 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.8, 167.1, 150.5, 150.0, 146.4, 145.7, 140.1, 139.9, 139.4, 128.3, 127.8, 127.7, 127.6, 127.0, 126.6, 126.3, 126.1, 125.3, 120.1, 119.6, 106.0, 62.90, 61.92, 52.81, 52.77, 51.5, 17.9, 14.7; IR (KBr) ν 2945, 1740, 1701, 1548, 1492, 1264, 1221, 1096, 756, 737, 704 cm^{-1}; HRMS (EI) m/z calcd for $\rm C_{31}H_{29}NO_4$ 479.2097, found 479.2096.

Diethyl 6-(4-chlorophenyl)-1-ethyl-6-(4-methoxyphenyl)-7-methyl-4-phenyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (**4***j*): yellow solid; 60% yield; mp 99–100 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.40 (d, *J* = 7.5 Hz, 2H), 7.31–7.17 (m, SH), 7.14 (d, *J* = 8.4 Hz, 2H), 7.08 (d, *J* = 8.5 Hz, 2H), 6.83 (d, *J* = 8.5 Hz, 2H), 6.03 (s, 1H), 4.58 (q, *J* = 6.0 Hz, 1H), 4.19–4.02 (m, 2H), 3.80–3.55 (m, 5H), 3.07– 2.58 (m, 2H), 1.35–1.27 (t, *J* = 6.9 Hz, 3H), 1.23–1.13 (m, 6H), 0.69 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.6, 166.0, 157.5, 147.5, 145.6, 141.1, 131.8, 131.5, 129.4, 128.6, 127.8, 127.6, 126.5, 126.3, 113.8, 102.7, 63.0, 61.7, 60.4, 60.2, 55.2, 53.3, 19.3, 16.2, 13.5, 13.4; IR (KBr) ν 2981, 1738, 1698, 1552, 1510, 1255, 1093, 1037, 832, 701 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₃₄H₃₆ClNO₅ 573.2282, found 573.2285.

Diethyl 1-ethyl-6,7-dimethyl-4,6-diphenyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (**4**k): white oil; 54% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.46 (d, *J* = 8.1 Hz, 1H), 7.39–7.14 (m, 9H), 6.14 (s, 0.5H), 5.57 (s, 0.5H), 4.37–4.22 (m, 1H), 4.16–4.01 (m, 1H), 3.76–3.41 (m, 4H), 3.00–2.66 (m, 0.5H), 2.54–2.38 (m, 0.5H), 1.55 (s, 1.5H), 1.44 (s, 1.5H), 1.41–1.31 (m, 3H), 1.24–1.16 (m, 1.5H), 1.16–1.07 (m, 3H), 0.90 (d, *J* = 6.6 Hz, 1.5H), 0.72–0.58 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.2, 170.0, 166.7, 166.4, 147.6, 146.8, 146.7, 146.6, 146.4, 143.0, 139.9, 137.5, 132.9, 131.7, 128.2, 127.9, 127.8, 126.72, 126.67, 126.5, 126.2, 126.0, 125.9, 103.2, 102.3, 66.4, 65.5, 61.9, 61.5, 60.2, 60.1, 52.6, 52.1, 51.3, 48.9, 30.0, 24.0, 17.4, 17.2, 15.8, 15.4, 13.7, 13.6, 13.3, 13.2; IR (film) ν 2979, 1737, 1698, 1549, 1444, 1258, 1217, 1097, 761, 701 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₂₈H₃₃NO₄ 447.2410, found 447.2406.

Dimethyl 7-ethyl-4,6,6-triphenyl-1-propyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (4l): white solid; 77% yield; mp 208–209 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.38–7.23 (m, 8H), 7.22–7.14 (m, 4H), 7.13–7.07 (m, 1H), 7.07–7.01 (m, 2H), 6.11 (s, 1H), 4.28 (d, *J* = 9.3 Hz, 1H), 3.70 (d, *J* = 2.0 Hz, 3H), 3.19 (d, *J* = 2.1 Hz, 3H), 2.53–2.20 (m, 2H), 1.65–1.24 (m, 4H), 1.16 (t, *J* = 7.2 Hz, 3H), 0.62 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.5, 166.9, 149.6, 146.5, 146.1, 142.7, 140.0, 133.8, 128.5, 128.3, 128.1, 127.9, 127.7, 126.5, 126.2, 126.0, 106.3, 69.9, 63.3, 60.0, 52.6, 51.5, 24.0, 23.0, 12.2, 11.1; IR (KBr) ν 2969, 1741, 1708, 1553, 1492, 1429, 1260, 1217, 1094, 753, 701 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₃₃H₃₅NO₄ 509.2566, found 509.2569.

Dimethyl 1-butyl-4,6,6-triphenyl-7-propyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (**4m**): white solid; 81% yield; mp 184–185 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.39–7.22 (m, 8H), 7.18 (t, *J* = 7.2 Hz, 4H), 7.12–7.01 (m, 3H), 6.11 (s, 1H), 4.36 (d, *J* = 9.5 Hz, 1H), 3.68 (s, 3H), 3.19 (s, 3H), 2.54–2.27 (m, 2H), 1.87–1.69 (m, 1H), 1.59–1.31 (m, 4H), 1.29–1.13 (m, 1H), 1.05–0.85 (m, 5H), 0.78 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.5, 166.8, 149.6, 146.6, 146.2, 142.7, 140.0, 133.8, 128.5, 128.3, 128.1, 127.9, 127.7, 126.4, 126.2, 126.1, 126.0, 106.3, 68.5, 63.3, 58.1, 52.5, 51.4, 33.5, 31.6, 20.8, 19.9, 14.5, 13.6; IR (KBr) ν 2960, 1738, 1696, 1547, 1444, 1253, 1202, 1093, 758, 702 cm⁻¹; HRMS (EI) *m/z* calcd for C₃₅H₃₉NO₄ 537.2879, found 537.2876.

Dimethyl 1-benzyl-4,6,6,7-tetraphenyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (**4n**): white solid; 78% yield; mp 153–154 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.43 (d, *J* = 7.6 Hz, 2H), 7.40–7.12 (m, 13H), 7.11–6.93 (m, 6H), 6.80 (t, *J* = 4.0 Hz, 2H), 6.75 (d, *J* = 7.6 Hz, 2H), 6.51 (s, 1H), 5.47 (s, 1H), 4.35 (d, *J* = 15.3 Hz, 1H), 4.10 (d, *J* = 15.3 Hz, 1H), 3.82 (s, 3H), 3.10 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.0, 167.6, 151.0, 144.8, 144.3, 143.8, 140.1, 139.8, 134.1, 130.4, 128.6, 128.5, 128.3, 128.2, 128.1, 127.7, 127.4, 127.3, 127.1, 126.6, 126.3, 126.2, 126.0, 101.4, 74.6, 56.2, 55.9, 52.7, 50.7; IR (KBr) ν 2980, 1727, 1694, 1553, 1492, 1444, 1356, 1261, 1142, 759, 701 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₄₁H₃₅NO₄ 605.2566, found 605.2563.

Diethyl 7,9,9-triphenyl-2,3,9,9a-tetrahydro-1H-pyrrolo[1,2-a]azepine-5,6-dicarboxylate (40): white solid; 64% yield; mp 141–142 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.36–7.28 (m, 4H), 7.28–7.12 (m, 11H), 6.06 (s, 1H), 4.52 (t, J = 6.7 Hz, 1H), 4.37–4.23 (m, 2H), 3.72–3.53 (m, 2H), 3.38 (dd, $J_1 = 17.4$ Hz, $J_2 = 7.6$ Hz, 1H), 3.13–3.02 (m, 1H), 2.13–2.03 (m, 2H), 1.64–1.50 (m, 1H), 1.34 (t, J = 7.1 Hz, 3H), 0.91–0.78 (m, 1H), 0.58 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.8, 166.2, 150.7, 146.9, 146.8, 143.4, 138.3, 136.0, 130.2, 128.3, 128.0, 127.8, 127.3, 126.9, 126.7, 126.4, 126.1, 102.3, 71.8, 61.6, 59.6, 51.1, 30.2, 23.1, 13.9, 13.3; IR (KBr) ν 2980, 1727, 1694, 1560, 1261, 1222, 1142, 1095, 759, 701 cm⁻¹; HRMS (EI) calcd for C₃₃H₃₃NO₄ 507.2410, found 507.2412.

Dimethyl 7,9,9-triphenyl-2,3,9,9a-tetrahydro-1H-pyrrolo[1,2-a]azepine-5,6-dicarboxylate (**4p**): white solid; 65% yield; mp 187– 188 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.36–7.29 (m, 4H), 7.29– 7.12 (m, 11H), 6.10 (s, 1H), 4.52 (t, *J* = 6.6 Hz, 1H), 3.86 (s, 3H), 3.36 (dd, *J* = 16.5, 8.1 Hz, 1H), 3.14–3.02 (m, 4H), 2.16–1.98 (m, 2H), 1.67–1.53 (m, 1H), 0.95–0.80 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 169.3, 166.6, 150.7, 146.8, 146.6, 143.3, 138.4, 135.8, 130.1, 128.3, 128.0, 127.8, 127.3, 126.7, 126.54, 126.48, 126.1, 101.9, 71.8, 59.4, 52.6, 51.2, 50.8, 30.2, 23.0; IR (KBr) ν 2948, 1735, 1701, 1560, 1442, 1271, 1225, 1143, 760, 702 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₃₁H₂₉NO₄ 479.2097, found 479.2098.

Diethyl 8,10,10-triphenyl-1,2,3,4,10,10a-hexahydropyrido[1,2-a]azepine-6,7-dicarboxylate (**4q**): white solid; 73% yield; mp 191–192 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.52–7.40 (m, 6H), 7.36–7.20 (m, 5H), 7.20–7.09 (m, 3H), 7.05 (t, *J* = 7.0 Hz, 1H), 6.72 (s, 1H), 4.73 (d, *J* = 8.7 Hz, 1H), 4.32–4.06 (m, 2H), 3.71–3.52 (m, 3H), 3.13 (t, *J* = 11.8 Hz, 1H), 1.86 (s, 1H), 1.79–1.55 (m, 5H), 1.27 (t, *J* = 7.0 Hz, 3H), 0.64 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.7, 166.6, 149.9, 146.2, 144.6, 144.2, 141.1, 133.4, 128.6, 127.9, 127.7, 126.8, 126.6, 126.2, 125.9, 125.8, 100.3, 72.5, 61.4, 58.9, 54.5, 54.0, 31.4, 27.4, 25.2, 13.9, 13.6; IR (KBr) ν 2935, 1729, 1691, 1547, 1492, 1445, 1256, 1117, 1040, 746, 702 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₁₄H₃₅NO₄ 521.2566, found 521.2568.

Dimethyl 1-ethyl-4,6,6,7-tetraphenyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (**4s**): white solid; 59% yield; mp 175–176 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.51 (d, J = 7.8 Hz, 2H), 7.37 (d, J = 7.6 Hz, 2H), 7.33–7.16 (m, 6H), 7.15–7.05 (m, 4H), 7.04–6.93 (m, 4H), 6.81 (d, J = 7.6 Hz, 2H), 6.52 (s, 1H), 5.61 (s, 1H), 3.78 (s, 3H), 3.42–3.11 (m, 2H), 3.05 (s, 3H), 1.11 (t, J = 7.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.3, 166.9, 150.6, 145.1, 144.5, 144.2, 141.1, 140.2, 133.3, 129.9, 128.8, 128.1, 128.0, 127.8, 127.6, 127.3, 127.1, 126.5, 126.34, 126.29, 126.0, 100.9, 57.0, 52.5, 50.6, 50.4, 14.4; IR (KBr) ν 2947, 1738, 1698, 1557, 1266, 1445, 1126, 910, 725, 699 cm⁻¹; HRMS (EI) *m/z* calcd for C₃₆H₃₃NO₄ 543.2410, found 543.2411.

Diethyl 1-ethyl-4,6,6,7-tetraphenyl-6,7-dihydro-1H-azepine-2,3dicarboxylate (**4t**): white solid; 52% yield; mp 165–166 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, J = 7.8 Hz, 2H), 7.39 (d, J = 7.5 Hz, 2H), 7.33–7.16 (m, 6H), 7.15–7.06 (m, 4H), 7.05–6.95 (m, 4H), 6.83 (d, J = 7.4 Hz, 2H), 6.48 (s, 1H), 5.62 (s, 1H), 4.22 (q, J = 7.0 Hz, 2H), 3.54 (q, J = 7.1 Hz, 2H), 3.44–3.10 (m, 2H), 1.27 (t, J = 7.1 Hz, 3H), 1.10 (t, J = 7.1 Hz, 3H), 0.57 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.6, 166.4, 150.7, 145.1, 144.8, 144.3, 141.3, 140.5, 133.0, 129.9, 128.8, 128.2, 127.9, 127.8, 127.5, 127.3, 127.1, 126.4, 126.3, 126.1, 101.0, 77.7, 61.5, 59.2, 57.0, 50.3, 14.5, 13.8, 13.4; IR (KBr) ν 2977, 1734, 1690, 1554, 1493, 1441, 1257, 1220, 1132, 700 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₃₈H₃₇NO₄ 571.2723, found 571.2716.

Diethyl 8,10,10-triphenyl-3,4,10,10a-tetrahydro-1H-[1,4]oxazino-[4,3-a]azepine-6,7-dicarboxylate (4r): white solid; 34% yield; mp 172–173 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.51–7.39 (m, 6H), 7.36–7.25 (m, 4H), 7.22–711 (m, 3H), 7.07 (t, J = 7.3 Hz, 1H), 6.86 (s, 1H), 4.96 (d, J = 9.0 Hz, 1H), 4.32–4.16 (m, 2H), 3.84 (dd, $J_1 =$ 34.0 Hz, $J_2 = 11.1$ Hz, 2H), 3.69–3.48 (m, 4H), 3.47–3.32 (m, 2H), 1.30 (t, J = 7.1 Hz, 3H), 0.65 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.2, 166.0, 150.2, 144.6, 144.4, 143.3, 141.9, 133.4, 128.8, 128.0, 127.9, 126.7, 126.4, 126.2, 126.0, 103.6, 73.2, 71.3, 67.4, 61.7, 59.1, 52.2, 13.9, 13.5; IR (KBr) ν 2977, 1735, 1695, 1560, 1365, 1261, 1122, 1075, 748, 702 cm⁻¹; HRMS (EI) m/z calcd for C₃₃H₃₃NO₅ 523.2359, found 523.2351.

Dimethyl 1-methyl-4,6,6,7-tetraphenyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (**4u**): white solid; 32% yield; mp 194–195 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.47 (d, *J* = 7.7 Hz, 2H), 7.39 (d, *J* = 7.5 Hz, 2H), 7.30 (t, *J* = 7.2 Hz, 4H), 7.25–7.17 (m, 2H), 7.14–7.05 (m, 4H), 7.01 (t, *J* = 7.5 Hz, 2H), 7.05–6.97 (m, 2H), 6.75 (d, *J* = 7.5 Hz, 2H), 6.56 (s, 1H), 5.41 (s, 1H), 3.82 (s, 3H), 3.05 (s, 3H), 2.93 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.0, 166.8, 151.1, 144.7, 144.6, 144.5, 140.2, 140.0, 133.0, 129.8, 128.8, 128.0, 127.9, 127.72, 127.69, 127.5, 127.2, 126.5, 126.41, 126.37, 126.0, 100.2, 81.2, 56.5, 52.5, 50.6, 41.3; IR (KBr) ν 2947, 1741, 1698, 1558, 1494, 1448, 1270, 1131, 755, 699 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₃₅H₃₁NO₄ 529.2253, found 529.2250.

Diethyl 1-methyl-4,6,6,7-tetraphenyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (**4v**): white solid; 20% yield; mp 170–171 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, J = 7.7 Hz, 2H), 7.40 (d, J = 7.3 Hz, 2H), 7.34–7.16 (m, 6H), 7.15–7.07 (m, 4H), 7.02 (t, J = 7.5 Hz, 2H), 6.98–6.90 (m, 2H), 6.77 (d, J = 7.5 Hz, 2H), 6.54 (s, 1H), 5.42 (s, 1H), 4.26 (q, J = 7.1 Hz, 2H), 3.65–3.41 (m, 2H), 2.95 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H), 0.55 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.2, 166.3, 151.2, 144.8, 144.7, 144.6, 140.5, 140.1, 132.6, 129.8, 127.93, 127.87, 127.7, 127.6, 127.4, 127.2, 126.4, 126.34, 126.28, 126.2, 100.1, 81.3, 61.5, 59.0, 56.4, 41.1, 13.8, 13.4; IR (KBr) ν 2927, 1734, 1695, 1629, 1560, 1266, 1134, 1078, 721, 699 cm⁻¹; HRMS (EI) m/z calcd for C₃₇H₃₅NO₄ 557.2566, found 557.2569.

Dimethyl 1-isopropyl-4,6,6,7-tetraphenyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (4w): white solid; 23% yield; mp 173–174 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, *J* = 7.8 Hz, 2H), 7.37 (d, *J* = 7.6 Hz, 2H), 7.33–7.01 (m, 12H), 6.95 (t, *J* = 7.3 Hz, 2H), 6.82 (d, *J* = 7.8 Hz, 2H), 6.49 (s, 1H), 5.78 (s, 1H), 3.93–3.82 (m, 1H), 3.78 (s, 3H), 3.06 (s, 3H), 1.46 (d, *J* = 6.4 Hz, 3H), 0.73 (d, *J* = 6.7 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.4, 167.5, 150.7, 145.4, 144.4, 144.1, 142.3, 140.1, 133.7, 130.5, 128.7, 128.1, 128.0, 127.8, 127.5, 127.1, 126.7, 126.4, 126.2, 125.9, 71.7, 57.1, 56.7, 52.4, 50.6, 24.7, 19.9; IR (KBr) ν 2947, 1738, 1669, 1538, 1494, 1431, 1262, 1105, 910, 735, 699 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₃₇H₃₅NO₄ 557.2566, found 557.2569.

Diethyl 1-isopropyl-4,6,6,7-tetraphenyl-6,7-dihydro-1H-azepine-2,3-dicarboxylate (**4**x): white solid; 16% yield; mp 167–168 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.56 (d, J = 7.4 Hz, 2H), 7.41 (d, J = 7.1 Hz, 2H), 7.35–7.18 (m, 5H), 7.18–7.01 (m, 7H), 6.95 (t, J = 7.3 Hz, 2H), 6.83 (d, J = 7.3 Hz, 2H), 6.46 (s, 1H), 5.79 (s, 1H), 4.33–4.21 (m, 2H), 4.09–3.82 (m, 1H), 3.54 (q, J = 6.2 Hz, 2H), 1.46 (d, J = 6.3 Hz, 3H), 1.25 (t, J = 7.0 Hz, 3H), 0.76 (d, J = 6.5 Hz, 3H), 0.59 (t, J = 7.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.6, 166.9, 151.0, 145.4, 144.7, 144.3, 142.6, 140.5, 133.2, 130.5, 128.8, 128.2, 127.9, 127.8, 127.4, 127.1, 126.7, 126.4, 126.2, 126.1, 101.7, 71.7, 61.4, 59.1, 57.0, 56.2, 24.9, 19.9, 13.7, 13.4; IR (KBr) ν 2981, 1734, 1695, 1546, 1493, 1248, 1222, 1101, 1030, 699 cm⁻¹; HRMS (EI) m/z calcd for C₃₉H₃₉NO₄ 585.2879, found 585.2877.

Dimethyl 1-isobutyl-7-isopropyl-4,6,6-triphenyl-6,7-dihydro-1Hazepine-2,3-dicarboxylate (**4**y): white solid; 17% yield; mp 137– 138 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.51 (d, *J* = 7.7 Hz, 2H), 7.43 (d, *J* = 7.3 Hz, 2H), 7.37–7.26 (m, 6H), 7.21 (t, *J* = 7.3 Hz, 1H), 7.13 (dd, *J*₁ = 14.9 Hz, *J*₂ = 7.5 Hz, 3H), 7.02 (t, *J* = 7.3 Hz, 1H), 6.56 (s, 1H), 4.78 (d, *J* = 3.4 Hz, 1H), 3.66 (s, 3H), 3.15 (s, 3H), 2.98–2.85 (m, 2H), 2.23–2.09 (m, 1H), 1.72–1.62 (m, 1H), 1.08 (d, *J* = 7.0 Hz, 3H), 0.98 (d, *J* = 6.8 Hz, 3H), 0.94 (d, *J* = 6.6 Hz, 3H), 0.58 (d, *J* = 6.6 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 169.8, 166.8, 149.7, 148.8, 145.0, 142.0, 140.8, 131.8, 128.29, 128.28, 128.0, 127.6, 126.4, 125.8, 103.3, 72.3, 64.2, 59.9, 52.3, 51.1, 35.4, 26.2, 25.6, 21.3, 20.9, 19.6; IR (KBr) ν 2960, 1741, 1709, 1547, 1256, 1214, 1109, 1088, 750, 702 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₃₅H₃₉NO₄ 537.2879, found 537.2891.

Diethyl 4-(diphenylmethylene)-1-morpholino-3-phenylcyclobut-2-ene-1,2-dicarboxylate (5): yellow solid; 31% yield; mp 98–99 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, J = 3.6 Hz, 2H), 7.34–7.26 (m, 3H), 7.09 (t, J = 6.9 Hz, 3H), 6.99 (t, J = 6.8 Hz, 3H), 6.95–6.82 (m, 4H), 4.27–4.01 (m, 4H), 3.68 (d, J = 3.6 Hz, 4H), 2.85 (s, 4H), 1.22 (t, J = 7.1 Hz, 3H), 1.09 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.8, 162.4, 161.5, 139.1, 138.7, 136.9, 136.2, 130.9, 130.5, 130.2, 128.4, 128.3, 128.0, 127.6, 127.4, 127.3, 126.9, 78.0, 67.5, 60.9, 60.4, 48.8, 14.03, 13.95; IR (KBr) ν 2925, 1743, 1704, 1444, 1330, 1243, 1177, 1117, 762, 698 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₁₃H₃₃NO₅ 523.2359, found 523.2366. Dimethyl 2-benzyl-5-(diphenylmethylene)-1-methyl-4-phenyl-2,5-dihydro-1H-pyrrole-2,3-dicarboxylate (**6a**): yellow solid; 45% yield; mp 119–120 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.43–7.31 (m, 3H), 7.22–7.07 (m, 5H), 6.91–6.59 (m, 10H), 6.36 (s, 1H), 6.28 (d, *J* = 6.0 Hz, 1H), 3.87 (s, 3H), 3.62–3.42 (m, 5H), 2.42 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 171.1, 163.8, 153.6, 150.5, 143.4, 141.9, 136.3, 134.2, 132.4, 131.6, 130.8, 130.3, 128.8, 128.4, 127.9, 127.5, 126.8, 126.6, 126.5, 125.5, 125.4, 115.1, 79.0, 52.8, 51.4, 37.9, 34.3; IR (KBr) ν 2951, 1730, 1617, 1439, 1366, 1238, 1172, 1106, 758, 697 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₃₅H₃₁NO₄ 529.2253, found 529.2249.

Diethyl 2-benzyl-5-(diphenylmethylene)-1-methyl-4-phenyl-2,5dihydro-1H-pyrrole-2,3-dicarboxylate (**6b**): yellow solid; 56% yield; mp 114–115 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.41–7.31 (m, 3H), 7.22–7.06 (m, 5H), 6.88–6.59 (m, 10H), 6.36 (s, 1H), 6.28 (d, *J* = 7.3 Hz, 1H), 4.41–4.25 (m, 2H), 4.02 (q, *J* = 6.9 Hz, 2H), 3.59 (d, *J* = 14.4 Hz, 1H), 3.47 (d, *J* = 14.5 Hz, 1H), 2.43 (s, 3H), 1.37 (t, *J* = 7.0 Hz, 3H), 0.96 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.4, 163.4, 153.2, 150.9, 143.5, 142.0, 136.5, 134.4, 132.9, 132.3, 131.7, 130.8, 130.3, 128.8, 128.5, 127.9, 127.5, 126.8, 126.5, 125.43, 125.37, 114.6, 79.0, 61.6, 60.2, 37.7, 34.3, 14.4, 13.7; IR (KBr) ν 2983, 1728, 1700, 1617, 1378, 1214, 1175, 1035, 758, 698 cm⁻¹; HRMS (EI) *m/z* calcd for C₃₇H₃₅NO₄ 557.2566, found 557.2574.

Dimethyl 4-(2,2-diphenylvinyl)-1-isopropyl-4,5-diphenyl-4,5-dihydro-1H-pyrrole-2,3-dicarboxylate (**7a**): white solid; 49% yield; mp 174–175 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.47 (t, *J* = 7.5 Hz, 2H), 7.38 (d, *J* = 7.8 Hz, 2H), 7.34–7.18 (m, 7H), 7.09–6.95 (m, 5H), 6.89 (s, 2H), 6.76 (s, 2H), 6.20 (s, 1H), 5.49 (s, 1H), 3.99 (s, 3H), 3.53 (s, 3H), 3.01–2.86 (m, 1H), 0.79 (d, *J* = 7.0 Hz, 3H), 0.59 (d, *J* = 6.7 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.3, 164.9, 153.5, 145.1, 143.2, 142.9, 140.6, 137.0, 136.3, 131.3, 128.8, 128.3, 128.0, 127.9, 127.5, 127.43, 127.38, 127.2, 127.1, 127.0, 125.9, 108.3, 75.0, 58.2, 52.8, 50.9, 48.8, 20.5, 20.2; IR (KBr) ν 2948, 1750, 1685, 1576, 1491, 1222, 1135, 789, 723, 703 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₃₇H₃₅NO₄ 557.2566, found 557.2565.

Diethyl 4-(2,2-diphenylvinyl)-1-isopropyl-4,5-diphenyl-4,5-dihydro-1H-pyrrole-2,3-dicarboxylate (**7b**): white solid; 52% yield; mp 131–132 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.46 (t, *J* = 7.5 Hz, 2H), 7.40 (d, *J* = 7.3 Hz, 2H), 7.33–7.16 (m, 7H), 7.09–6.96 (m, 5H), 6.91 (s, 2H), 6.76 (s, 2H), 6.23 (s, 1H), 5.46 (s, 1H), 4.45 (q, *J* = 7.1 Hz, 2H), 4.17–3.89 (m, 2H), 3.04–2.89 (m, 1H), 1.48 (t, *J* = 7.1 Hz, 3H), 0.99 (t, *J* = 7.1 Hz, 3H), 0.79 (d, *J* = 7.0 Hz, 3H), 0.59 (d, *J* = 6.7 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 164.6, 164.4, 153.5, 145.3, 143.1, 142.8, 140.6, 137.3, 136.8, 131.3, 128.7, 128.3, 128.0, 127.5, 127.3, 127.2, 127.0, 126.9, 125.8, 108.6, 74.7, 61.9, 59.0, 58.4, 48.9, 20.5, 20.3, 14.3, 14.0; IR (KBr) ν 2980, 1745, 1685, 1588, 1443, 1367, 1219, 1184, 1132, 702 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₃₉H₃₉NO₄ 585.2879, found 585.2880.

Dimethyl 2-(isobutylamino)-3-[(E)-1,3,3-triphenylprop-1-en-1-yl]maleate (**8**): white solid; 58% yield; mp 94–95 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.31 (s, 5H), 7.10–6.91 (m, 10H), 4.56 (s, 1H), 3.81 (s, 3H), 3.34 (s, 3H), 2.58–2.35 (m, 2H), 2.14 (s, 1H), 1.82–1.68 (m, 1H), 0.93 (t, *J* = 6.0 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 172.2, 169.1, 149.5, 146.3, 142.2, 140.4, 139.3, 131.6, 130.2, 128.5, 128.2, 128.1, 127.5, 127.4, 127.2, 126.6, 62.2, 55.7, 52.4, 51.3, 28.6, 20.5; IR (KBr) ν 3384, 2958, 1735, 1686, 1581, 1492, 1431, 1252, 757, 700 cm⁻¹; HRMS (EI) *m*/*z* calcd for C₃₁H₃₃NO₄ 483.2410, found 483.2408.

Procedure for the Preparation of 9. To a solution of diethylamine (2a) (1 mmol) in dry dichloromethane (3 mL) was added methyl propiolate (1 mmol), and the solution was stirred at room temperature for 10 min. Then, propargylic alcohol (3a) (1 mmol), 4 Å molecular sieves (400 mg), and BF_3 ·Et₂O (1 mmol) were added in sequence. The mixture was stirred for 1 h and then evaporated under vacuum. The residue was purified by silica gel column chromatography with a hexane/EtOAc mixture (10:1, v/v) to afford pure 9 (191 mg, 52% yield).

(*Z*)-Methyl 2-formyl-3,5,5-triphenylpenta-2,4-dienoate (9): yellow solid; 52% yield; mp 127–128 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.30 (s, 1H), 7.40–7.26 (m, 5H), 7.17–6.96 (m, 9H), 6.87 (d, *J* = 7.3 Hz, 2H), 3.85 (s, 3H); ¹³C NMR (100 MHz, CDCl₃)

 δ 189.8, 167.0, 159.2, 154.2, 141.6, 139.0, 135.3, 134.3, 130.7, 130.4, 129.2, 128.5, 128.3, 128.0, 127.7, 127.4, 126.4, 52.5; IR (KBr) ν 2855, 1729, 1651, 1568, 1329, 1310, 1269, 1147, 775, 702 cm $^{-1}$; HRMS (EI) m/z calcd for C₂₅H₂₀O₃ 368.1412, found 368.1405.

ASSOCIATED CONTENT

Supporting Information

Copies of ¹H and ¹³C NMR spectra and crystallographic information (CIF files) for compounds **4a**, **6b**, **7a**, and **8**. This material is available free of charge via the Internet at http:// pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: pinglu@zju.edu.cn; orgwyg@zju.edu.cn.

ACKNOWLEDGMENTS

We thank the National Natural Science Foundation of China (Grants 21032005 and 20872128) for financial support.

REFERENCES

(1) (a) Gijsen, H. J. M.; Berthelot, D.; Zaja, M.; Brône, B.; Geuens, I.; Mercken, M. J. Med. Chem. 2010, 53, 7011. (b) Tomasi, S.; Renault, J.; Martin, B.; Duhieu, S.; Cerec, V.; Roch, M. L.; Uriac, P.; Delcros, J.-G. J. Med. Chem. 2010, 53, 7647. (c) Grunewald, G. L.; Caldwell, T. M.; Li., Q. F.; Criscione, K. R. J. Med. Chem. 2001, 44, 2849. (d) Kukla, M. J.; Breslin, H. J.; Diamond, C. J.; Grous, P. P.; Ho, C. Y.; Miranda, M.; Rodgers, J. D.; Sherill, R. G.; Clercq, E. D.; Pauwels, R.; Andries, K.; Moens, L. J.; Janssen, M. A. C.; Janssen, P. A. J. J. Med. Chem. 1991, 34, 3187. (e) Kimball, S. D.; Floyd, D. M.; Das, J.; Hunt, J. T.; Krapcho, J.; Rovnyak, G.; Duff, K. J.; Lee, V. G.; Moquin, R. V. J. Med. Chem. 1992, 35, 780. (f) Neumeyer, J. L.; Kula, N. S.; Baldessarini, R. J.; Baindur, N. J. Med. Chem. 1992, 35, 1466. (g) Grunewald, G. L.; Dahanukar, V. H.; Criscione, K. R. Bioorg. Med. Chem. 2001, 9, 1957.

(2) (a) Miah, M. A. J.; Hudlicky, T.; Reed, J. W. *The Alkaloids*; Academic Press: New York, 1998; Vol. 51, p 199. (b) Morita, H.; Arisaka, M.; Yoshida, N.; Kobayashi, J. *Tetrahedron* **2000**, *56*, 2929.

(3) For reviews on seven-membered ring formation, see: (a) Yet, L.

Tetrahedron 1999, 55, 9349. (b) Yet, L. Chem. Rev. 2000, 100, 2963. (c) Kantorowski, E. J.; Kurth, M. J. Tetrahedron 2000, 56, 4317.

(d) Maier, M. E. Angew. Chem., Int. Ed. 2000, 39, 2073.

(4) Katritzky, A. R., II, Ed. Comprehensive Heterocyclic Chemistry; Pergamon: New York, 1996; Vol. 9, p 21.

(5) Tietze, L. F.; Schimpf, R. Synthesis 1993, 876.

(6) (a) Ohno, H.; Hamaguchi, H.; Ohata, M.; Kosaka, S.; Tanaka, T. *J. Am. Chem. Soc.* **2004**, *126*, 8744. (b) Lyaskovskyy, V.; Bergander, K.; Fröhlich, R.; Würthwein, E.-U. *Org. Lett.* **2007**, *9*, 1049. (c) Vieira, T. O.; Alper, H. *Org. Lett.* **2008**, *10*, 485.

(7) Shapiro, N. D.; Toste, F. D. J. Am. Chem. Soc. 2008, 130, 9244.
(8) Wender, P. A.; Pedersen, T. M.; Scanio, M. J. C. J. Am. Chem. Soc. 2002, 124, 15154.

(9) (a) Sutton, A. E.; Seigal, B. A.; Finnegan, D. F.; Snapper, M. L. J. Am. Chem. Soc. 2002, 124, 13390. (b) Wu, C.-J.; Madhushaw, R. J.; Liu, R.-S. J. Org. Chem. 2003, 68, 7889. (c) Kaïm, L. E.; Grimaud, L.; Oble, J. J. Org. Chem. 2007, 72, 5835. (d) Hanessian, S.; Sailes, H.; Munro, A.; Therrien, E. J. Org. Chem. 2003, 68, 7219. (e) Pearson, W. H.; Aponick, A.; Dietz, A. L. J. Org. Chem. 2006, 71, 3533. (f) Martínez-Estibalez, U.; Sotomayor, N.; Lete, E. Tetrahedron Lett. 2007, 48, 2919.

(10) For selected reviews on the chemistry of allenes, see: (a) Krause, N.; Hashmi, A. S. K. *Modern Allene Chemistry*; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2004; Vols. 1 and 2. (b) Schreiner, P. R.; Navarro-Vázquez, A.; Prall, M. Acc. Chem. Res. 2005, 38, 29. (c) Ma, S. M. Chem. Rev. 2005, 105, 2829. (d) Ma, S. M. Acc. Chem. Res. 2009, 42, 1679. (e) Wei, L. L.; Xiong, H.; Hsung, R. P. Acc. Chem. Res. 2003, 36, 773. (f) Sydnes, L. K. Chem. Rev. 2003, 103, 1133.

(11) (a) Meyer, K. H.; Schüster, K. Ber. Dtsch. Chem. Ges. 1922, 55, 819. (b) Swaminathan, S.; Narayan, K. V. Chem. Rev. 1971, 71, 429. (c) Edens, M.; Boerner, D.; Chase, C. R.; Nass, D.; Schiavelli, M. D. J. Org. Chem. 1977, 42, 3403. (d) Engel, D. A.; Dudley, G. B. Org. Biomol. Chem. 2009, 7, 4149.

(12) (a) Klett, M. W.; Johnson, R. P. J. Am. Chem. Soc. **1985**, 107, 3963. (b) Bernard, J.; Schnieders, C.; Mullen, K. J. Chem. Soc., Chem. Commun. **1985**, 12. (c) Ishikawa, T.; Aikawa, T.; Mori, Y.; Saito, S. Org. Lett. **2003**, 5, 51.

(13) (a) Yin, G. W.; Zhu, Y. X.; Zhang, L.; Lu, P.; Wang, Y. G. Org. Lett. **2011**, 13, 940. (b) Zhu, Y. X.; Yin, G. W.; Hong, D.; Lu, P.; Wang, Y. G. Org. Lett. **2011**, 13, 1024.

(14) (a) Shchukin, A. O.; Vasil'ev, A. V. Russ. J. Org. Chem. 2007, 43, 784. (b) Huang, W.; Zheng, P. Z.; Zhang, Z. X.; Liu, R.; Chen, Z. X.; Zhou, X. G. J. Org. Chem. 2008, 73, 6845. (c) Wang, S. Y.; Zhu, Y. X.; Wang, Y. G.; Lu, P. Org. Lett. 2009, 11, 2615. (d) Zhang, X. X.; Teo, W. T.; Chan, P. W. H. Org. Lett. 2009, 11, 4990. (e) Chatterjee, P. N.; Roy, S. J. Org. Chem. 2010, 75, 4413.

(15) Yao, L.-F.; Shi, M. Org. Lett. 2007, 9, 5187.

(16) Zhang, X.; Teo, W. T.; Sally.; Chan, P. W. H. J. Org. Chem. 2010, 75, 6290.

(17) Ziyaei-Halimehjani, A.; Saidi, M. R. Tetrahedron Lett. 2008, 49, 1244.

(18) CCDC 827903 contains the supplementary crystallographic data for **4a**. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via http://www.ccdc.cam.ac. uk/data request/cif.

(19) The diethyl 2-(diethylamino)maleate is pure according to the ¹H NMR spectrum: ¹H NMR (400 MHz, CDCl₃) δ 4.60 (s, 1H), 4.41 (q, *J* = 7.2 Hz, 2H), 4.09 (q, *J* = 7.1 Hz, 2H), 3.19 (q, *J* = 7.1 Hz, 4H), 1.38 (t, *J* = 7.2 Hz, 3H), 1.27–1.15 (m, 9H).

(20) Yao, L.-F.; Shi, M. Chem.-Eur. J. 2009, 15, 3875.

(21) CCDC 827904 contains the supplementary crystallographic data for 6b.

(22) CCDC 833052 contains the supplementary crystallographic data for 7a.

(23) CCDC 833053 contains the supplementary crystallographic data for 8.

(24) Alizadeh, A.; Rezvanian, A. Synthesis 2008, 11, 1747.

(25) (a) Sakaguchi, T.; Okuno, Y.; Tsutsumi, Y.; Tsuchikawa, H.; Katsumura, S. *Org. Lett.* **2011**, *13*, 4292. (b) Janardanan, D.; Sunoj, R. B. *Org. Biomol. Chem.* **2011**, *9*, 1642.

(26) For review articles about azomethine ylides, see: (a) Adrio, J.; Carretero, J. C. *Chem. Commun.* **2011**, 47, 6784. (b) Pinho e Melo, T. M. V. D. *Eur. J. Org. Chem.* **2006**, *13*, 2873. (c) Coldham, I.; Hufton, R. *Chem. Rev.* **2005**, *105*, 2765.

(27) (a) Soret, A.; Blanco, L.; Deloisy, S. Lett. Org. Chem. 2006, 3, 648. (b) Garner, P.; Arya, F.; Ho, W.-B. J. Org. Chem. 1990, 55, 412.

(28) The pK_a values for diethylamine (10.98), dipropylamine (11.00), dibutylamine (11.25), pyrrolidine (11.27), piperidine

(11.22), morpholine (8.36), and diisobutylamine (10.50) indicate the inductive effect of the oxygen in morphorine. These data are from: Hall, H. K. J. Am. Chem. Soc. **1957**, 79, 5441.

(29) Engel, D. A.; Dudley, G. B. Org. Lett. 2006, 8, 4027.